BioNTech SE (ETR:22UA)

Market Cap	22.79B +19.6%
Revenue (ttm)	2.87B +4.3%
Net Income	-1.14B
EPS	-4.70
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,178
Average Volume	40,537
Open	92.60
Previous Close	94.80
Day's Range	91.35 - 93.75
52-Week Range	68.30 - 110.90
Beta	1.59
RSI	65.42
Earnings Date	May 5, 2026

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 7,807
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 22UA

Financial Performance

In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.